Softwr

Healthcare · head to head

Rad AI vs Techcyte

Rad AI logo

Rad AI

Healthcare

Generative reporting and follow-up tracking for radiology, positioned outside the diagnostic device boundary

From
On request
Rated
-
Full reviewWebsite
Techcyte logo

Techcyte

Healthcare

AI digital pathology across clinical, veterinary and environmental laboratory disciplines

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Rad AI the products are not FDA cleared devices and are not intended to be, so any claim that Rad AI improves diagnostic accuracy is unsupported; what has been measured is reporting speed and follow-up completion, not detection.; Techcyte regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • They diverge on capability: Rad AI covers Impressions, Techcyte covers Fusion Parasitology Suite.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Rad AI and Techcyte actually diverge.

Attributes where Rad AI and Techcyte differ
AttributeRad AITechcyte
PlatformsWindows, Web, CloudWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Rad AI

  • Impressions
  • Reporting
  • Continuity
  • Style learning
  • Omni Reconcile
  • PACS and dictation embedding
  • Patient outreach workflows
  • Audit reporting

Only in Techcyte

  • Fusion Parasitology Suite
  • Cervical cytology
  • Haematology
  • Urinalysis
  • Bacteriology and mycology
  • Vetcyte
  • Scanner agnostic ingestion
  • Remote review

What people use each for

The jobs each tool is most often brought in to do.

Rad AI

  • A private radiology practice whose read volume has grown faster than it can recruit and that wants dictation time per study reduced without changing PACSnot Techcyte
  • A health system losing revenue and exposing itself to liability because recommended follow-up imaging on incidental findings is never bookednot Techcyte
  • A radiology department standardising impression quality across a mixed group of employed and locum radiologistsnot Techcyte
  • A group deploying an AI tool that must not trigger a device validation programme, because governance capacity is already consumed by a triage algorithm rolloutnot Techcyte

Techcyte

  • A clinical laboratory that cannot recruit technologists for high volume manual parasitology screening and needs AI pre screening with human releasenot Rad AI
  • A veterinary reference laboratory processing large volumes of faecal and blood smears that wants Vetcyte to triage the normal casesnot Rad AI
  • A European laboratory that can deploy the CE marked products clinically, which is where Techcyte regulatory position is strongestnot Rad AI
  • An environmental testing laboratory needing consistent microscopy classification across analysts and sitesnot Rad AI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Rad AI

  • The products are not FDA cleared devices and are not intended to be, so any claim that Rad AI improves diagnostic accuracy is unsupported; what has been measured is reporting speed and follow-up completion, not detection.
  • Generated impressions require radiologist review and signature, so the time saving evaporates in any group whose radiologists rewrite the draft rather than edit it, and adoption varies sharply by individual.
  • It is bound to your dictation platform, so a group planning to move off PowerScribe should sequence that decision first or expect to redo the Rad AI integration.
  • Continuity depends on the quality of recommendation language in historical reports, and departments with inconsistent phrasing get poor recall until reporting practice is standardised.
  • Pricing is not published and is structured per radiologist or per study depending on the product mix, which makes it hard to compare against image-analysis AI vendors that price per scan.

Techcyte

  • Regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • Slide scanning for parasitology, haematology and cytology needs multi plane imaging that a histology scanner may not produce, so a laboratory that already owns a scanner often has to buy new hardware, which becomes the biggest line in the project.
  • Each discipline is licensed separately, so a laboratory wanting parasitology, urinalysis and haematology assembles three modules and three validation studies rather than buying one platform.
  • AI pre screening does not remove the need for a qualified reviewer to release results, so the staffing saving is in review time per slide, not in headcount, and business cases that assume otherwise do not hold.
  • Techcyte covers a very wide set of disciplines, which means depth varies between them, and the maturity of a newer module is not the maturity of the parasitology or cytology products that made the company its name.

Pricing, plan by plan

Rad AI

On request
  • Rad AI platform$undefined/year
    • Priced per radiologist or per study volume depending on product and contract
    • Impressions, Reporting and Continuity licensed separately
    • Annual subscription with implementation and integration scoped per site

Techcyte

On request
  • Techcyte$undefined/year
    • Priced per slide or per annual specimen volume by discipline
    • Each discipline module licensed separately
    • Slide scanning hardware bought separately, not included

Which should you pick?

Choose Rad AI if

  • You need impressions.
  • You work on Windows, Web, Cloud.
  • You also want reporting.
Rad AI review

Choose Techcyte if

  • You need fusion parasitology suite.
  • You also want cervical cytology.
Techcyte review

Questions people ask

Is Rad AI or Techcyte better?
Neither clearly leads. Rad AI starts at On request and Techcyte at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Rad AI or Techcyte?
Rad AI starts at On request and Techcyte at On request.
Does Rad AI or Techcyte run on more platforms?
Rad AI runs on Windows, Web, Cloud. Techcyte runs on Web.
What is Rad AI best used for?
Rad AI is most often used for a private radiology practice whose read volume has grown faster than it can recruit and that wants dictation time per study reduced without changing pacs, a health system losing revenue and exposing itself to liability because recommended follow-up imaging on incidental findings is never booked, a radiology department standardising impression quality across a mixed group of employed and locum radiologists, a group deploying an ai tool that must not trigger a device validation programme, because governance capacity is already consumed by a triage algorithm rollout. Of those, a private radiology practice whose read volume has grown faster than it can recruit and that wants dictation time per study reduced without changing pacs and a health system losing revenue and exposing itself to liability because recommended follow-up imaging on incidental findings is never booked are not what Techcyte is typically brought in for.
What can Rad AI do that Techcyte cannot?
Rad AI covers Impressions, Reporting, Continuity, Style learning. Techcyte covers Fusion Parasitology Suite, Cervical cytology, Haematology, Urinalysis.

Answered from the vendors’ own pages

Rad AI: Is Rad AI FDA cleared?

No, and by design. The products draft text and manage follow-up workflow rather than interpreting images, so they fall outside the device pathway. Treat any diagnostic accuracy claim with scepticism.

Techcyte: Is Techcyte FDA cleared?

Not uniformly. Several United States offerings, including the Fusion Parasitology Suite, are labelled research use only and not for diagnostic use in the United States. Check the regulatory status of each specific module for your country before purchase.

Rad AI: Does the radiologist still sign the report?

Yes. Output is a draft that the radiologist reviews and signs; nothing is released autonomously.

Techcyte: Can we use it clinically in Europe?

Techcyte solutions are CE marked and clinically deployed across Europe, which is where its regulatory position is strongest. Confirm the current certificate for the specific module.

Rad AI: Which product actually pays for itself?

Continuity has the clearest financial case, because recommended follow-up imaging that gets completed is billable work that currently does not happen.

Techcyte: Does it eliminate the need for a technologist?

No. AI pre screens and prioritises, but a qualified reviewer still releases results. The saving is in review time per slide.

Rad AI: Will it work with our dictation system?

It is deepest with Nuance PowerScribe. Confirm your specific dictation and PACS combination before contracting, because integration depth is the main deployment variable.

Techcyte: Do we need a specific scanner?

Techcyte works with several scanner vendors, but disciplines such as parasitology and haematology need multi plane imaging that many histology scanners cannot produce, so confirm hardware compatibility early.

Share

Related pages

More on Rad AI

More on Techcyte

Keep looking

Other head to heads